 HomeNewsLexicon`s Sotagliflozin demonstrates benefits in heart failure and blood glucose control across the full range of kidney function in new analysis of clinical data

Lexicon`s Sotagliflozin demonstrates benefits in heart failure and blood glucose control across the full range of kidney function in new analysis of clinical data

2021-11-19

Lexicon Pharmaceuticals, Inc. recently announced that a new analysis evaluating the clinical benefit of Lexicon`s investigational drug, sotagliflozin, in heart failure and blood glucose control across the full range of kidney function was presented at the virtual American Heart Association Scientific Sessions 2021.

Heart and kidney disease are often interconnected, with chronic kidney disease considered to be an independent risk factor for heart failure and cardiovascular disease. It is estimated that around half of patients with type 2 diabetes have chronic kidney disease.

[In this new analysis of pooled clinical data from the SOLOIST and SCORED trials, sotagliflozin consistently reduced total cardiovascular deaths, hospitalizations for heart failure, and urgent visits for heart failure across the full range of kidney function," said Dr. Bhatt. [Sotagliflozin, with its dual mechanism of SGLT1 and SGLT2 inhibition, also significantly reduced hemoglobin A1c across the full range of kidney function studied, including patients with severe renal impairment or an estimated glomerular filtration rate between 25 and 30 ml/min/1.73m2, with a magnitude of effect that has not been reported in studies of selective SGLT2 inhibitors."

The pooled analysis of clinical data from the SOLOIST and SCORED trials involved a total of 11,806 patients with diabetes and heart failure or cardiovascular risk factors.

[This continued research provides further evidence of the rapid, robust and broad benefits observed in the SOLOIST and SCORED studies of sotagliflozin in heart failure," said Lexicon senior vice president and chief medical officer Craig B. Granowitz, M.D., Ph.D. [We believe these results will strengthen the new drug application we plan on filing with the U.S. Food and Drug Administration around year-end. If approved, we believe sotagliflozin has the potential to become an important new therapeutic option for heart failure in patients with type 2 diabetes. With its unique dual SGLT1 and SGLT2 inhibition, sotagliflozin continues to show benefits we believe to be differentiating for a broad range of patients suffering from heart failure or at a higher risk for heart failure."

Previous: KRAS mutant lung cancer new drug: targeted drug Lumakras

Next: Eli Lilly's oral JAK inhibitor Olumiant (Baritinib): 9.3 years of treatment, with long-term good safety!

 HomeNewsLexicon`s Sotagliflozin demonstrates benefits in heart failure and blood glucose control across the full range of kidney function in new analysis of clinical data

Shandong Haohong Biotechnology Co., Ltd.